Next Article in Journal
“Just Caring”: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?
Previous Article in Journal
Motivations and Barriers to Sharing Biological Samples: A Case Study
Open AccessArticle

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

1
Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, MD 20814, USA
2
EJS Health Solutions, LLC, 1653 Pennfield Drive Thorofare, West Deptford, NJ 08086, USA
3
Biocerna, LLC, Gaithersburg, MD 20879, USA
4
Opus Three, LLC, Gaithersburg, MD 20878, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2013, 3(2), 111-123; https://doi.org/10.3390/jpm3020111
Received: 17 April 2013 / Revised: 24 May 2013 / Accepted: 4 June 2013 / Published: 10 June 2013
We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sources, regulatory approval/ recommendation of testing, reliance on labeling for information, and perception that patients have benefited from testing. Physicians use pharmacogenomic testing information from drug labeling, highlighting the importance of labeling information that is conducive to practice application. View Full-Text
Keywords: pharmacogenomics; physician; drug labeling; survey pharmacogenomics; physician; drug labeling; survey
MDPI and ACS Style

Stanek, E.J.; Sanders, C.L.; Frueh, F.W. Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information. J. Pers. Med. 2013, 3, 111-123.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop